Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

NCT: NCT05318105 · TERMINATED

NCT IDNCT05318105
StatusTERMINATED
Start Date2022-06-28
Completion2026-04-07
SponsorNuwellis, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.

Frequently Asked Questions

What is Ultrafiltration Versus IV Diuretics in Worsening Heart Failure?

Ultrafiltration Versus IV Diuretics in Worsening Heart Failure is a clinical trial registered under NCT05318105. Current status: TERMINATED.

What is the status of NCT05318105?

The current status of NCT05318105 (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) is: TERMINATED.

When did Ultrafiltration Versus IV Diuretics in Worsening Heart Failure start?

Ultrafiltration Versus IV Diuretics in Worsening Heart Failure started on 2022-06-28.

Related Devices

K233515Dual Lumen Extended Length Catheter (dELC), 6F, 12 cm (320101), Dual Lumen Extended Length Catheter (dELC), 6F, 16 cm (320102)Nuwellis, Inc. K252226Dual Lumen Extended Length Catheter (dELC), 6F, 12cm (320101); Dual Lumen Extended Length Catheter (dELC), 6F, 16 cm (320102)Nuwellis, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑